Analysis of concentrations of monomethyl fumarate in patients with multiple sclerosis: results from routine health care
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F24%3AE0111120" target="_blank" >RIV/00843989:_____/24:E0111120 - isvavai.cz</a>
Result on the web
<a href="https://www.eurekaselect.com/article/140787" target="_blank" >https://www.eurekaselect.com/article/140787</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/0118715273302279240529104919" target="_blank" >10.2174/0118715273302279240529104919</a>
Alternative languages
Result language
angličtina
Original language name
Analysis of concentrations of monomethyl fumarate in patients with multiple sclerosis: results from routine health care
Original language description
Background: Dimethyl fumarate is used to treat patients with relapsing-remitting multiple sclerosis. After ingestion, it is rapidly hydrolyzed to the active primary metabolite monomethyl fumarate. Objective: The main objective of our study was to analyze serum concentrations of monomethyl fumarate during routine health care in patients with multiple sclerosis treated with a fixed dose of dimethyl fumarate. Methods: In the pilot cross-sectional study, data from 42 patients treated with dimethyl fumarate at a dose of 240 mg twice daily were collected. Concentrations of the active metabolite monomethyl fumarate were determined at 1-8 h (median, 3 h) or 10-14 h (median, 13 h) after taking the dose. The relationship between monomethyl fumarate concentrations and absolute lymphocyte count was evaluated. Results: Concentrations of monomethyl fumarate ranged from 2.5-3177.9 µg/L, with most concentrations being undetectable approximately 10 hours after administration. In the 1-8 h (median, 3 h) post-dose subgroup, the concentration/dose ratio ranged widely from 0.04-6.62. The median concentration of monomethyl fumarate in the group with the absolute lymphocyte count <0.8 x 10^9/l was more than four times higher than in the group with the absolute lymphocyte count ?0.8 x 10^9/l (median 440.1 µg/L versus 98.4 µg/L). Conclusion: The wide interindividual variability in monomethyl fumarate pharmacokinetics could contribute to the differential response to dimethyl fumarate in multiple sclerosis patients. A nonsignificant but noticeable trend was observed in the relationship of higher serum monomethyl fumarate concentrations to absolute lymphocyte counts.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30210 - Clinical neurology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
CNS & neurological disorders drug targets
ISSN
1871-5273
e-ISSN
1996-3181
Volume of the periodical
23
Issue of the periodical within the volume
12
Country of publishing house
AE - UNITED ARAB EMIRATES
Number of pages
8
Pages from-to
1516-1523
UT code for WoS article
001241320100001
EID of the result in the Scopus database
2-s2.0-85204997645